VYNE Therapeutics (VYNE) Other Non Operating Income (2017 - 2026)
VYNE Therapeutics (VYNE) posted Other Non Operating Income of $231000.0 for Q1 2026, down 82.23% on a QoQ basis from $1.3 million in Q2 2025, and down 61.11% year-over-year from $594000.0 in Q1 2025.
VYNE Therapeutics (VYNE) Other Non Operating Income (2017 - 2026) Analysis & Trends
VYNE Therapeutics' Other Non Operating Income history runs 10 years deep, the most recent figure standing at $231000.0 for Q1 2026.
- Quarterly Other Non Operating Income fell 61.11% year-over-year to $231000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (down 12.28% YoY) and the FY2025 annual result came in at $3.0 million, down 21.31% from the prior year.
- Other Non Operating Income was $231000.0 for Q1 2026 at VYNE Therapeutics, down from $1.3 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $1.3 million in Q2 2025 and bottomed at -$3000.0 in Q1 2022.
- A 5-year average of $513866.7 and a median of $280000.0 in 2023 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2023 — Other Non Operating Income soared 8866.67% — and 2026, when it tumbled 61.11%.
- VYNE Therapeutics' Other Non Operating Income stood at $236000.0 in 2022, then soared by 188.14% to $680000.0 in 2023, then rose by 11.76% to $760000.0 in 2024, then jumped by 71.05% to $1.3 million in 2025, then sank by 82.23% to $231000.0 in 2026.
- Business Quant data shows VYNE's Other Non Operating Income at $231000.0 in Q1 2026, $1.3 million in Q2 2025, and $594000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 231,000.00 |
| Jun 30, 2025 | 1.30 Mn |
| Mar 31, 2025 | 594,000.00 |
| Dec 31, 2024 | 760,000.00 |
| Sep 30, 2024 | 934,000.00 |
| Jun 30, 2024 | 1.00 Mn |
| Mar 31, 2024 | 1.14 Mn |
| Dec 31, 2023 | 680,000.00 |
| Sep 30, 2023 | 163,000.00 |
| Jun 30, 2023 | 280,000.00 |
| Mar 31, 2023 | 263,000.00 |
| Dec 31, 2022 | 236,000.00 |
| Sep 30, 2022 | 78,000.00 |
| Jun 30, 2022 | 52,000.00 |
| Mar 31, 2022 | -3,000.00 |
| Dec 31, 2021 | 26,000.00 |
| Sep 30, 2021 | -35,000.00 |
| Jun 30, 2021 | -69,000.00 |
| Mar 31, 2021 | -57,000.00 |
| Dec 31, 2020 | -31,000.00 |